Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Team Maps Epigenetic Changes in Stem Cells

August 17, 2010 6:16 am | News | Comments

Having charted the occurrence of a common chemical change that takes place while stem cells decide their fates and progress from precursor to progeny, a team of scientists has produced the first-ever epigenetic landscape map for tissue differentiation.


New Targets Discovered For Anti-Angiogenesis Drugs

August 17, 2010 6:13 am | News | Comments

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice.


Pfizer Granted Approval For New XYNTHA Delivery Method

August 17, 2010 6:04 am | News | Comments

Pfizer Inc. announced that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients.


FDA Questions Expanded Cymbalta Use

August 17, 2010 5:52 am | by Matthew Perrone | News | Comments

Federal health scientists are questioning whether the antidepressant Cymbalta is safe and effective enough to be approved for use against chronic pain.


Feds Push to Withdraw ProAmatine

August 17, 2010 5:50 am | by Matthew Perrone | News | Comments

Federal health regulators are pushing to withdraw a blood pressure drug that has been on the market for 14 years in spite of the manufacturer's failure to submit evidence that it actually helps patients.


Berkshire Hathaway Ups Stake In J & J

August 17, 2010 5:47 am | by Josh Funk | News | Comments

Warren Buffett's Berkshire Hathaway Inc. has partially rebuilt the stake in Johnson & Johnson he reduced over the past two years to raise cash for other investments.


Lilly Halts Disappointing Alzheimer's Treatment

August 17, 2010 5:43 am | News | Comments

Drugmaker Eli Lilly and Co. has stopped developing a potential Alzheimer's disease treatment in late-stage testing after patients taking the drug fared worse than those on a placebo.


HDL Mimetic Targets Atherosclerosis

August 16, 2010 10:58 am | by Narendra Lalwani, PhD, Chief Scientific Officer, Cerenis Therapeutics, Inc, Ann Arbor, Mich. | News | Comments

CER-001 is an experimental high-density lipoproteins mimetic being developed by Cerenis Therapeutics. This class of drugs removes cholesterol from the vessel wall to treat high-risk atherosclerosis, including acute coronary syndrome.


New Targets, Dual Agonists Increase Possibilities for Treating Diabetes

August 16, 2010 10:45 am | by Fritz French, Chief Executive Officer, Marcadia Biotech, Carmel, Ind. | News | Comments

In recent years, treatment strategies for type 2 diabetes have been focused on the development of novel therapeutic options, especially new drugs targeting the incretin system.


UV-VIS Flash Purification

August 16, 2010 8:33 am | Product Releases | Comments

Biotage, a leading developer of tools and technology for medicinal and analytical chemistry, announces the introduction of the Isolera UV-VIS flash purification system.


Phosphorylation Tool

August 16, 2010 8:30 am | Product Releases | Comments

Sage-N Research Inc., a leader in computational proteomics, announces the integration of the first commercially available phosphorylation tool using mass spectrometry into its drug discovery platform.


New Method Predicts Nanointeractions

August 16, 2010 8:12 am | News | Comments

Researchers at North Carolina State University have developed a method for predicting the ways nanoparticles will interact with biological systems – including the human body.


Leaders Advocate Expanded Cancer Care In Developing World

August 16, 2010 8:10 am | News | Comments

Once thought to be a problem primarily in the developed world, cancer is now a leading cause of death and disability in poorer countries. Almost two-thirds of the 7.6 million cancer deaths in the world occur in low- and middle-income countries.


Medco Buys Clinical Trial Tech Maker

August 16, 2010 8:02 am | News | Comments

Pharmacy benefits manager Medco Health Solutions Inc. said it will buy United BioSource Corp., which develops technology used in clinical trials and patient monitoring, for $730 million in cash.


Vectibix Disappoints in Phase 3 Trial

August 16, 2010 7:59 am | News | Comments

Amgen announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.